newsfilter
← Latest News
GlobeNewswire·

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing